Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study
(2023) In Journal of Translational Medicine- Abstract
- Introduction
Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium may interact with tumour selenoprotein expression. However, there is no matched analysis to date.
Methods
This study included 1453 patients with newly diagnosed breast cancer from the multicentric prospective Sweden Cancerome Analysis Network – Breast study. Total serum selenium, selenoprotein P and glutathione peroxidase 3 were analysed at time of diagnosis. Bulk RNA-sequencing was conducted in matched tumour tissues. Fully adjusted Cox regression models with an interaction term were... (More) - Introduction
Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium may interact with tumour selenoprotein expression. However, there is no matched analysis to date.
Methods
This study included 1453 patients with newly diagnosed breast cancer from the multicentric prospective Sweden Cancerome Analysis Network – Breast study. Total serum selenium, selenoprotein P and glutathione peroxidase 3 were analysed at time of diagnosis. Bulk RNA-sequencing was conducted in matched tumour tissues. Fully adjusted Cox regression models with an interaction term were employed to detect dose-dependent interactions of circulating selenium with the associations of tumour selenoprotein mRNA expression and mortality.
Results
237 deaths were recorded within ~ 9 years follow-up. All three serum selenium biomarkers correlated positively (p Conclusions
This first unbiased analysis of serum selenium with the breast cancer selenotranscriptome identified an effect-modification of selenium on the associations of DIO1, SELENOM, and DIO3 with prognosis. Selenium substitution in patients with DIO1-expressing tumours merits consideration to improve survival. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/cc3cf504-6a38-4a10-8d1e-3a48fa241e84
- author
- organization
-
- LUCC: Lund University Cancer Centre
- Surgery (research group)
- Breastcancer-genetics
- Tumor Cell Biology (research group)
- Division of Translational Cancer Research
- Transl oncogenomics
- Translational Oncogenomics (research group)
- Breast cancer treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Breast Cancer Surgery (research group)
- Surgery (Lund)
- Familial Breast Cancer (research group)
- EpiHealth: Epidemiology for Health
- publishing date
- 2023-09-23
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Translational Medicine
- article number
- 658
- publisher
- BioMed Central (BMC)
- external identifiers
-
- scopus:85172372078
- pmid:37741974
- ISSN
- 1479-5876
- DOI
- 10.1186/s12967-023-04502-y
- project
- Sweden Cancerome Analysis Network - Breast (SCAN-B): a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
- language
- English
- LU publication?
- yes
- id
- cc3cf504-6a38-4a10-8d1e-3a48fa241e84
- date added to LUP
- 2023-09-23 13:39:13
- date last changed
- 2023-12-24 03:00:02
@article{cc3cf504-6a38-4a10-8d1e-3a48fa241e84, abstract = {{Introduction<br/>Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium may interact with tumour selenoprotein expression. However, there is no matched analysis to date.<br/>Methods<br/>This study included 1453 patients with newly diagnosed breast cancer from the multicentric prospective Sweden Cancerome Analysis Network – Breast study. Total serum selenium, selenoprotein P and glutathione peroxidase 3 were analysed at time of diagnosis. Bulk RNA-sequencing was conducted in matched tumour tissues. Fully adjusted Cox regression models with an interaction term were employed to detect dose-dependent interactions of circulating selenium with the associations of tumour selenoprotein mRNA expression and mortality.<br/>Results<br/>237 deaths were recorded within ~ 9 years follow-up. All three serum selenium biomarkers correlated positively (p Conclusions<br/>This first unbiased analysis of serum selenium with the breast cancer selenotranscriptome identified an effect-modification of selenium on the associations of DIO1, SELENOM, and DIO3 with prognosis. Selenium substitution in patients with DIO1-expressing tumours merits consideration to improve survival.}}, author = {{Demircan, Kamil and Bengtsson, Ylva and Samson Chillon, Thilo and Vallon-Christersson, Johan and Sun, Qian and Larsson, Christer and Malmberg, Martin and Saal, Lao and Ryden, Lisa and Borg, Åke and Manjer, Jonas and Schomburg, Lutz}}, issn = {{1479-5876}}, language = {{eng}}, month = {{09}}, publisher = {{BioMed Central (BMC)}}, series = {{Journal of Translational Medicine}}, title = {{Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study}}, url = {{http://dx.doi.org/10.1186/s12967-023-04502-y}}, doi = {{10.1186/s12967-023-04502-y}}, year = {{2023}}, }